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Abstract
Background: Emergence of viral variants that escape CTL control is a major hurdle in HIV
vaccination unless such variants affect gene regions that are essential for virus replication. Vaccine-
induced multispecific CTL could also be able to control viral variants replication. To explore these
possibilities, we extensively characterized CTL responses following vaccination with an epitope-
based lipopeptide vaccine and challenge with pathogenic SIVmac251. The viral sequences
corresponding to the epitopes present in the vaccine as well as the viral loads were then
determined in every macaque following SIV inoculation.
Results: In most cases, the emergence of several viral variants or mutants within vaccine CTL
epitopes after SIV challenge resulted in increased viral loads except for a single macaque, which
showed a single escape viral variant within its 6 vaccine-induced CTL epitopes.
Conclusion: These findings provide a better understanding of the evolution of CD8+ epitope
variations after vaccination-induced CTL expansion and might provide new insight for the
development of an effective HIV vaccine.
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Several lines of evidence strongly suggest the key role
played by human immunodeficiency virus (HIV)- and
simian immunodeficiency virus (SIV)-specific cytotoxic T
lymphocyte (CTL) responses in the containment of viral
replication and of the disease. CTL responses precede anti-
body production and coincide with clearance of primary
viremia [1-3]. Virus plasma levels within the first 3
months of HIV or SIV infection are predictive of clinical
evolution and AIDS-free survival [4-6] and in vivo-deple-
tion of CD8+ T cells during primary infection of rhesus
macaques increases plasma viral load [7,8]. Recently and
for the first time, anti-GAG CTL induced by a vaccine were
shown to be capable to control viral load following intra-
venous pathogenic SIVmac239 challenge [9].
Several reports showed that anti-HIV immunodominant
CTL responses select viral variants bearing mutations that
diminish MHC class I binding and/or CTL recognition
[10-13]. The viral escape hypothesis has been reinforced
by a longitudinal study by Evans et al. in a family of MHC-
defined monkeys [14]. This study showed that the pro-
gressive amino acid changes in T epitopes throughout the
course of infection allowed viruses to escape CTL recogni-
tion. Nevertheless, a viral mutation in a CTL epitope can
alter the fitness of the virus which can partially loose its
infectivity and variability [9]. It is then also very important
to characterize which viral regions are essential for main-
taining good fitness of the virus. Indeed, vaccination
inducing CTL directed against the latter regions allows
either a viral control by the CTL or the emergence of viral
escape mutants with shift of the virus toward a defective
virus.
Very few studies addressed the question of SIV escape due
to mutations within multiple epitopes recognized by vac-
cination-induced CTL. Most published reports focused on
particular epitopes recognized by vaccine-induced CTL,
such as the epitope MamuA1 CM9 in anti-GAG-SIV-
immunized macaques [15] or NEF 128–136 [16].
Although a large debate exists on the role of breadth and
magnitude of CD8+ CTL responses in the control of viral
replication, several groups have demonstrated in HIV-
infected humans that broad specific recognition of CD8+
T cell epitopes was associated with favorable outcome
[17-19]. In addition, broad CTL responses are frequently
observed in long term survivors [20,21].
With the aim to induce multispecific CTL responses, we
previously immunized a cohort of 8 macaques with SIV-
NEF- and GAG-derived lipopeptides coupled to tetanus
toxoid (TT) 830–846 lipopeptide [22]. Seven of these
macaques exhibited CD8+ CTL responses. Two of the
responding animals had broad multispecific cytotoxic
reactivities directed against four and six SIV epitopes,
respectively. We now challenged these 8 macaques with
pathogenic SIVmac251 and monitored the evolution of
viral sequences in epitopic regions recognized by CTL as
well as viral load during the first 8 months after SIV inoc-
ulation
Results
1- CTL activities after vaccination with lipopeptides
Prior to SIV infection, CTL activities had been induced in
seven out of the eight immunized macaques (Figure 1).
Two macaques 92109 and 92129 had strong and multi-
specific CTL responses that recognized five and three long
peptides, respectively. One macaque 92127 had CTL
responses against two long peptides with a lower cytotoxic
activity. Four other macaques, 92102, 92105, 92120 and
92125, had CTL recognizing a single long peptide and the
last macaque, 92117, failed to recognize any peptide.
In order to precisely define the CTL-induced responses, we
tested overlapping short peptides spanning the entire
sequence of the lipopeptides. Two of the vaccinated
macaques, namely 125 and 105, had CTL recognizing a
single NEF epitope, NEF 169–178 and NEF 128–136
epitopes, respectively (Table 1). The CTL response of
macaque 127 was bi-specific (directed against peptide
NEF 116–126 and an unidentified short peptide included
in NEF 128–147) and macaque 129 had CTL recognizing
4 epitopes (NEF 128–136, NEF 169–178, NEF 201–211,
NEF 211–219). Finally, macaque 109 had CTL that recog-
nized 6 epitopes (NEF 101–110, NEF 116–126, NEF 128–
136, NEF 169–178, NEF 215–225, GAG 266–275).
2- Comparison of NEF and GAG CTL epitope sequences 
included in lipopeptides and in SIVmac251 isolate
Since sequences of the immunizing peptide were derived
from the BK-28 SIV clone, epitope variants in the virus
inoculum could represent potential viral escape from CTL
recognition in lipopeptide-vaccinated macaques [16,23].
We analyzed sequences of viral variants included in the
SIVmac251 isolate used for the challenge within the
regions present in the lipopeptide vaccine. In the
sequenced gag gene, we observe no variation within all
sequenced SIVmac251 viruses with regards to the peptide
sequence GAG 246–281 (data not shown). Similarly,
epitopes NEF 116–126 and NEF 169–178 were perfectly
conserved (Table 2). In contrast, the other NEF viral CTL
epitopic regions varied within the challenge virus. Indeed,
within epitopes NEF 211–219 and NEF 215–225, a single
amino acid variation was observed in only one of 11 viral
sequences (9%) at position 218 (T → A). In epitopes NEF
128–136 and NEF 201–211, two of 11 viral sequences
(18%) showed an amino acid change, 136 (A → T) and
202 (K → Q and K → R). Finally, we observed variations
of all viral sequences within epitope NEF 101–110, partic-
ularly in the first half, with changes at positions 101 (S →Page 2 of 12
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Cytotoxic activities detected in the 7 responder macaques against long peptides after lipopeptide vaccinationFigure 1
Cytotoxic activities detected in the 7 responder macaques against long peptides after lipopeptide vaccination. 
Only the positive cytotoxic responses against long peptide-sensitized target cells of the responder macaques are shown, all 
long peptides having been tested in each monkey.
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Virology Journal 2006, 3:65 http://www.virologyj.com/content/3/1/65P), 102 (V → M), 103 (R → M or R → K), 105 (K → R),
and 110 (A → T).
3- Evolution of NEF viral quasispecies within CTL epitopes 
in macaques following SIV challenge
All vaccinated macaques became infected after SIV chal-
lenge. To follow the evolution of NEF epitopic viral
sequences, we sequenced the entire nef gene in the viruses
isolated 35 to 41 weeks after SIV challenge from the vacci-
nated macaques that had CTL against NEF epitopes (Table
3).
Among macaques with anti-NEF induced CTL, the NEF
169–178 sequence was stable (macaque 125). Macaque
105 had a significant increase in 136T viral variants
(18%→ 44%). 122L mutants (40%) occurred in macaque
127. In macaque 129, there were many mutations in NEF
201–211 and NEF 211–219 epitopes and emergence of an
exclusive 136T variant (100%) in the NEF 128–136
epitope. No variation was evidenced in the NEF 169–178
epitope, as observed in macaque 125 also. As for macaque
109 that lacked detectable cell-associated viremia, viral
DNA integrated in PBMC was identified and sequenced. A
single viral variant was detected in this latter animal
within all the NEF lipopeptide-induced CTL epitopes.
4- Monitoring of viral load following SIV challenge
High level plasma viral RNA was observed 15 days post-
inoculation in all macaques (Figure 2a). The three control
animals (954, 956, 959) had a high peak viremia at day 15
post-inoculation. Two of them (954 and 959), with the
highest viral load, died at month 4. All but one vaccinated
macaque (109), had plasma viral RNA levels that
remained high following viremia peak. In contrast, RNA
viremia in macaque 109 was consistently undetectable
from the third month post-challenge. Macaque 105's
plasma viral load was only transiently controlled at week
23.
Cell-associated viremia was measured in all macaques
during the same period (Figure 2b). All animals had high
cellular viremia except for macaque 109 that had undetec-
table levels from the third month after SIV-infection.
Moreover, median levels of plasma viral RNA and cell
associated viremia, evaluated between weeks 9 and 35,
were high except for macaque 109 (Table 4).
5- Longitudinal follow-up of CTL responses following SIV 
challenge in macaques 109 and 129
CTL responses were tested both between 10 to 13 weeks
and between 47 to 60 weeks after SIV challenge by stimu-
lating PBMC with ConA as described in section methods.
CTL responses against the epitopes recognized by lipopep-
tide-induced CTL (shown in Figure 3a) were no longer
detectable in macaque 109 following SIV challenge (Fig-
ure 3b). In contrast, macaque 129 had CTL against NEF
the 128–136 peptide that were observed at week 13 but
became undetectable at week 47 following SIV challenge
(Figure 3b).
Discussion and conclusion
In a previous work, we immunized eight rhesus macaques
with SIV-NEF and -GAG lipopeptides combined with a
promiscuous TT 830–846 lipopeptide [22]. In the present
study, all animals and 3 control macaques were intrave-
nously challenged with pathogenic SIVmac251. This path-
ogenic viral isolate consisted of a mixture of several viral
quasispecies of the nef gene that display several differ-
ences in particular within the NEF epitopes recognized by
lipopeptide-induced CTL.
Table 1: Epitopic specificities found in 5 immunized macaques
Effector cellsa % Specific lysisc at the E/T ratiod of
Macaque # Target cellsb 100:1 33:1 11:1 4:1
92125 None 38 34 25 19
NEF 169–178 86e 87 70 54
92105 None 22 14 12 2
NEF 128–136 34 24 13 5
92127 None 28 21
NEF 116–126 43 32
92129 None 8 3 2 0
NEF 128–136 46 34 28 9
NEF 201–211 22 16 16 5
NEF 211–219 19 16 10 4
None 52 44 30
NEF 169–178 65 54 33
92109 None 14 11 11 5
NEF 101–110 26 22 16
NEF 128–136 28 23
None 41 34 41 27
NEF 116–126 57 45 48 34
None 25 21
NEF 169–178 89 75
None 14 11 5
NEF 215–225 41 36 22
None 19 9 7 3
GAG -275 40 24 16 6
a CTL cell lines were obtained from PBMCs of the 8 immunized 
macaques following specific-stimulation with the 7 long peptides in 
vitro.
b Target cells were autologous B-LCLs immortalized by the herpes 
papio virus and incubated with short peptides (10µM).
c Target cells (5×103) were labeled with 51Cr and incubated for 4 h 
with various numbers of target cells.
d E/T ratio, effector to target ratio.
e CRT was considered positive if the specific-51Cr release observed 
against peptide-pulsed target cells exceeded that observed on B-LCLs 
without peptide by 10% at two E/T ratio.Page 4 of 12
(page number not for citation purposes)
Virology Journal 2006, 3:65 http://www.virologyj.com/content/3/1/65Five macaques had post-immunization anti-NEF CTL and
one of them (macaque 125) had CTL directed only against
NEF 169–178, which is perfectly conserved within the
challenge SIVmac251 quasispecies. No variation was
observed in the sequence of this epitope 35 weeks follow-
ing SIV challenge. Likewise, this epitope was conserved in
both macaques 129 and 109. This result is in accordance
with our previous data in another macaque immunized
with a similar mixture of NEF- and GAG- lipopeptides
[23]. These observations suggest that NEF 169–178 is a
stable epitope that is not submitted to the pressure of CTL
selection.
Recently, Watkins et al. [24] demonstrated that a high
level of CTL against the single GAG 181–189 epitope was
not sufficient to control viremia. In rhesus macaques
immunized with DNA-gag-pol-IL2, emergence of viral
mutants occurred in GAG 181–189 after SIV-challenge
under the pressure of mono-epitope CTL [25,26]. This
viral escape was due to the selection of mutant viral
epitopic peptides unable to stably bind to MHC class I
molecules, as we have previously shown in lipopeptide-
vaccinated macaques within epitope NEF 128–136 [16]
and in HIV-infected patients [11]. In addition, the emer-
gence of such viral mutants had no effect on the viral load
[16], which suggests no effect on viral fitness.
In the present study, macaque 105 had lipopeptide
induced CTL against NEF 128–136, a non-conserved
epitope within the pathogenic SIVmac251 isolate, which
contains 18% of 136T and 82% of 136A quasispecies.
Forty weeks following SIV challenge of this monkey, the
percentage of 136T viruses had increased (45%) whereas
136A viruses decreased (55%). The persistence of the two
wild type variants within the single vaccine induced CTL
epitope did not affect viral replication. The NEF 116–126
epitope recognized by CTL after lipopeptide vaccination
in macaque 127 was perfectly conserved in SIV isolate
(NEF 116–126) as NEF 169–178 epitope but 122L
mutant occurred in 40% of the SIV quasispecies 40 weeks
after SIV infection. Nevertheless, the persistence of 60% of
wild type viral sequences likely allowed viral replication
to remain very high during clinical evolution in this
macaque without effect on the high viral fitness.
Three of the 4 epitopes recognized by lipopeptide-
induced CTL from macaque 129 were not conserved (NEF
128–136, NEF 201–211 and NEF 211–219) in
SIVmac251 isolates. The emergence of the wild type vari-
ants 136T (100%) was observed within the CTL epitope
NEF 128–136 after SIV challenge. Epitopes NEF 201–211
and 211–219 shifted by acquiring mutations that had no
effect on viral load and the persistence of wild type viral
sequences (22%) within these epitopes could also have
contributed to intense viral replication.
In macaque 109, three of the 6 epitopes recognized by
CTL following lipopeptide vaccination, namely epitopes
Table 2: Comparison between CTL epitope sequences included in lipopeptides and SIV mac251 isolate
pre-SIV challenge - CTL responses sequences of SIV mac251 challenge isolate
Macaque # epitopic peptides sequences
125 NEF 169–178 KTFGWLWKLV KTFGWLWKLV 11/11
105 NEF 128–136 GLEGIYYSA GLEGIYYS 9/11
GLEGIYY T 2/11
127 NEF 116–126 AIDMSHFIKEK AIDMSHFIKEK 11/11
129 NEF 128–136 GLEGIYYSA GLEGIYYSA 9/11
GLEGIYYST 2/11
NEF 169–178 KTFGWLWKLV KTFGWLWKLV 11/11
NEF 201–211 SKWDDPWGEVL SKWDDPWGEVL 9/11
SRWDDPWGEVL 1/11
SQWDDPWGEVL 1/11
NEF211–219 LAWKFDPTL LAWKFDPTL 10/11
LAWKFDPAL 1/11
109 NEF 101–110 SVRPKVPLRA PVMPRVPLRT 8/11
PVMPRVPLRA 1/11
SVRPKVPLRT 1/11
SMKPRVPLRT 1/11
NEF 116–126 AIDMSHFIKEK AIDMSHFIKEK 11/11
NEF 128–136 GLEGIYYSA GLEGIYYSA 9/11
GLEGIYYST 2/11
NEF 169–178 KTFGWLWKLV KTFGWLWKLV 11/11
NEF 215–225 FDPTLAYTYEA FDPTLAYTYEA 10/11
FDPALAYTYEA 1/11
GAG -175 WIQLGLQKCV WIQLGLQKCV 11/11Page 5 of 12
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perfectly conserved in SIVmac251 isolates used for the
challenge. Interestingly, after challenge, we did not
observe any variation within all sequenced NEF epitopes
from SIV-infected macaque in particular in epitope NEF
116–126, in contrast to the data in macaque 127. Within
epitopes NEF 101–110, NEF 128–136 and NEF 215–225,
only one viral variant issued from SIVmac251 was
selected and expanded in the absence of emergence of
new variations. We hence hypothesize that macaque 109
exerted a selection of few-replicative and non-pathogenic
viral variant following SIV challenge. This selection could
be the consequence of the vaccine induced CTL. However,
we cannot formally exclude the role of an uncontrolled
and random process.
CTL responses were evaluated in the two infected
macaques 109 and 129, 12 months post-challenge. They
were undetectable against all the identified vaccine pep-
tides except in macaque 129. In the latter animal, CTL
response against peptide 128–136 disappeared at week
47, following a 100% selection of 136T viral variant as
shown in Table 3 and previously observed [16].
CTL obtained following vaccination could play a key role
in the control of viremia. Decrease and control of viral
load have also been reported in macaques vaccinated with
MVA-gag-pol-env [27,28], MVA-nef [29], MVA-gag-pol [30],
ALVAC-gag-pol-env [31], NYVAC-gag-pol-env [32], adeno-
gag [33], DNA [34,35], a combination of DNA and MVA
[36,37] or a prime/boost with DNA/gag-Sendai virus [9]
and challenged with SIV or SHIV. In these studies, the
control of SIV/SHIV replication was clearly related to a
high magnitude of CTL recognizing NEF [29] or GAG
181–189 epitope in MamuA1 macaques [30,35], or to the
selection of a non pathogenic viral mutant in GAG 206–
216 (216S) CTL vaccine epitope [9]. Indeed, viral escape
by mutation in an epitope under CTL pressure can also
prevent virus replication. Matano et al [9] observed that
after vaccination with DNA/gag-Sendai and viral chal-
lenge, all macaques that controlled viral replication had a
mutation in GAG leading to the substitution of one resi-
due in GAG 206–216 (216S) CTL vaccine epitope by week
5 after challenge. This viral escape variant could have a
lower fitness than wild type SIVmac239, indicating that
the vaccine-induced CTL could have exerted a strong
immune pressure leading to clearance of the wild type
pathogenic SIV.
In our study, the emergence of several viral mutants in two
macaques (127 and 129) within vaccine CTL epitopes was
always associated with the persistence of the wild type
Table 3: Evolution of NEF viral quasispecies within CTL epitopes in macaques following SIV challenge
Macaque # sequences of epitopic peptides SIV mac251 sequences post-SIV challenge sequences weeks
125 NEF 169–178 KTFGWLWKLV KTFGWLWKLV 11/11 KTFGWLWKLV 10/10 35
105 NEF 128–136 GLEGIYYSA GLEGIYYSA 9/11
GLEGIYYST 2/11
GLEGIYYSA 5/9
GLEGIYYST 4/9
40
127 NEF 116–126 AIDMSHFIKEK AIDMSHFIKEK 11/11 AIDMSHFIKEK 6/10
AIDMSHLIKEK 4/10
40
129 NEF 128–136 GLEGIYYSA GLEGIYYSA 9/11
GLEGIYYST 2/11
GLEGIYYST 9/9 35
NEF 169–178 KTFGWLWKLV KTFGWLWKLV 11/11 KTFGWLWKLV 9/9
NEF 201–211 SKWDDPWGEVL SKWDDPWGEVL 9/11
SRWDDPWGEVL 1/11
SQWDDPWGEVL 1/11
SKWDDPWGEVL 2/9
AQWDDPWGEVL 3/9
AQWDDPWGEIL 1/9
AKWDDPWGEVL 2/9
SRWDDPWGEVL 1/9
NEF211–219 LAWKFDPTL LAWKFDPTL 10/11
LAWKFDPAL 1/11
LAWKFDPTL 2/9
LAWRFDPTL 3/9
LAWKFDSTL 3/9
LAWRFDSTL 1/9
109 NEF 101–110 SVRPKVPLRA PVMPRVPLRT 8/11
PVMPRVPLRA 1/11
SVRPKVPLRT 1/11
SMKPRVPLRT 1/11
PVMPRVPLRT 9/9 41
NEF 116–126 AIDMSHFIKEK AIDMSHFIKEK 11/11 AIDMSHFIKEK 9/9
NEF 128–136 GLEGIYYSA GLEGIYYSA 9/11
GLEGIYYST 2/11
GLEGIYYSA 9/9
NEF 169–178 KTFGWLWKLV KTFGWLWKLV 11/11 KTFGWLWKLV 9/9
NEF 215–225 FDPTLAYTYEA FDPTLAYTYEA 10/11
FDPALAYTYEA 1/11
FDPTLAYTYEA 9/9
GAG -275 WIQLGLQKCV WIQLGLQKCV 11/11 NDPage 6 of 12
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Virology Journal 2006, 3:65 http://www.virologyj.com/content/3/1/65virus and therefore was not concomitant with the decrease
of viral fitness. The occurrence of an exclusive viral escape
variant within several vaccine induced CTL epitopes was
observed in only one macaque (109) and could be associ-
ated either with a selection of a poor replicative virus or
with a control of viral replication by CTL.
These results tentatively bring a clue for a better under-
standing of SIV control and might provide new insight for
the development of an effective HIV vaccine.
Materials and methods
Lipopeptides and short peptides
Five peptides from the SIV-NEF protein were synthesized
from the sequence of the molecular clone SIV BK-28 (LP1
aa 101–126, LP2 aa 125–147, LP3 aa 155–178, LP4 aa
201–225, and LP5 aa 221–247). Two peptides from the
SIV-GAG protein were also produced (LP6 aa 165–195
and LP7 aa 246–281). These selected sequences were
identical to those previously reported [38] except for the
introduction of a Nε palmitoyl-lysylamide at the C-termi-
nal position. A tetanus toxoid (TT) 830–846 lipopeptide
was added to the seven SIV lipopeptides [22]. The
lipopeptides were synthesized by solid-phase synthesis as
previously described [39]. They were purified to more
than 90% homogeneity by reverse-phase HPLC and char-
acterized by amino acid composition and molecular mass
determination. In addition, overlapping short peptides
spanning the entire sequence of these lipopeptides were
synthesized by Neosystem (Strasbourg, France).
Immunization protocol and virus challenge
Eight rhesus macaques (Macaca mulatta) were immunized
with SIV-lipopeptides as previously described (three injec-
Evaluation of plasma viral RNA levels and cell-associated viremia in SIV-challenged macaquesFig re 2
Evaluation of plasma viral RNA levels and cell-associated viremia in SIV-challenged macaques. a- Plasma viral 
load in 8 lipopeptide-vaccinated (102, 105, 109, 117, 120, 125, 127, 129) and 3 naive (954, 956, 959) macaques was evaluated 
up to week 35 post-SIV infection using SIVmac bDNA assay. b- Cell-associated viremia was evaluated in 8 lipopeptide-vacci-
nated (102, 105, 109, 117, 120, 125, 127, 129) and 3 control (954, 956, 959) macaques up to 35 weeks post-SIV inoculation.
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Virology Journal 2006, 3:65 http://www.virologyj.com/content/3/1/65tions at one-month intervals) [22]. They were immunized
again 12 and 18 months after the end of the first vaccina-
tion cycle. They were challenged intravenously two weeks
after the second boost with 10 animal-infectious doses 50
(AID50) of the highly pathogenic SIVmac251 isolate,
kindly provided by A.M. Aubertin (Strasbourg, France).
Three non-vaccinated control macaques received the same
challenges. All animal experiments were performed in
accordance with European Union guidelines.
Characterization of CTL responses
The lipopeptide-induced CTL responses were examined
after the last mixed-micelle immunization by stimulating
macaque PBMCs with a mixture of the seven long free SIV
peptides corresponding to the sequences of peptides
included in lipopeptides. CTL lines were then tested
against autologous B lymphoblastoid cell lines (B-LCL)
sensitized by the same long peptides or by short peptides.
After SIV challenge, production of SIV antigens by infected
CD4+ cells for stimulation of CTL lines, was induced by
14 days stimulation of PBMC with 10 µg/ml concanavalin
A (Sigma, St.Louis, Mo.). Interleukine (IL) 2 (10 IU/ml,
Roche, Mannheim, Germany) was added on days 3, 7,
and 10 and cell concentration was adjusted to 5 × 105/ml
twice a week.
In vitro transformation of B cell lines
B lymphoblastoid cell lines (B-LCL) were generated as
previously described [38] and cultured in the same
medium as that used for the generation of CTL lines.
Chromium release test (CRT)
To sensitize target cells by peptides, B-LCL (106) were
incubated either overnight or for 1 h with long (10-5 M) or
short peptides (10-6 M) at 37°C in a humidified 5% CO2
atmosphere. B-LCL alone served as controls. B-LCL were
washed and labeled with 100 µCi Na251CrO4 (NEN Life
Science Products, Courtaboeuf Les Ullis, France) for 1 h,
washed twice, and used as target cells. CRT was performed
in V-bottomed 96-well microtiter plates. The cytolytic
activity of anti-SIV cell lines was measured by mixing
5,000 51 Cr-labeled target cells with effector cells at various
effector cell/target cell (E/T) ratios in a final volume of
200 µl/well. Duplicate wells were seeded for each E/T
ratio. Plates were incubated for 4 h at 37°C; 100 µl/well
of supernatant was then removed from each well and
counted. Spontaneous release was determined by incubat-
ing target cells with medium alone; it never exceeded 20%
of total 51Cr incorporated. Results were expressed as spe-
cific Cr release : 100 × experimental counts per minute
(cpm)- spontaneous cpm/maximum cpm – spontaneous
cpm. The within-sample variation never exceeded 5%.
CRT was considered positive when the specific-51Cr
release observed against peptide-pulsed target cells
exceeded that observed with B-LCL alone by 10% at two
effector/target (E/T) ratios.
Measurement of plasma viral RNA levels
SIV-RNA plasma levels were determined by using the SIV-
mac bDNA assay (Chiron Diagnostics, Emeryville, CA).
The detection threshold was 1500 DNA copies per millili-
ter of plasma.
Measurement of cell-associated viremia
To quantify cellular viremia, 105 CEM X 174 cell hybrids
(fusion product of human B-cell line 721.174 and human
T-cell line) were co-cultured with fivefold serial dilutions
Table 4: Median of plasma viral RNA and cell-associated viremia
plasma viral RNA Cell-associated viremia
Macaque # copies/ml median for weeks 9–35 SIV proviral copy/106 PBMC median for weeks 9–35
117 33 000 6
102 208 000 230
120 16 000 6
125 48 000 30
105 4 000 5
127 81 000 6
129 57 000 30
109 < 1500 0,1Page 8 of 12
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the presence of RT SIV antigen.
Sequencing of SIV genes
DNA preparation
PBMC were isolated as above and washed in RPMI
medium. Aliquots (107 cells) were incubated overnight at
52°C in 1 ml lysis buffer (10 mM Tris-HCl pH 8.3, 50 mM
KCl, 2.5 mM MgCl2, 0.45% Tween 20, and 400 µg/ml pro-
teinase K). DNA was extracted with phenol/chloroform
and precipitated with ethanol. The pellet was washed with
70% ethanol, dried, resuspended in 10 mM Tris pH 7.5
and quantified by measuring optical densities at 260 nm.
Polymerase chain reaction (PCR) amplification
Nested PCR was performed in 100 µl reaction mixtures
containing 200 µM of each deoxynucleotide triphosphate
(Pharmacia, Uppsala, Sweden), 10 mM Tris-HCl pH 8.3,
50 mM KCl, 1.5 mM MgCl2, 2.5 U Taq polymerase (Gibco
BRL, Life Technologies, Gaithersburg, MD), and 20 pmol
of primer (Genset, Paris, France). The primers used in the
first round of PCR were nef1 (5'-AGGCTCTCTGCGAC-
CCTACG-3') and nef2 (5'-AGAACCTCCCAGGGCT-
CAATCT-3'). VJ11 (5'-ATGGGTGGAGCTATTTCCATG-3')
and VJ12 (5'-TTAGCCTTCTTCTAACCTC-3') (encompass-
ing the entire nef gene) were used in the second round. For
gag gene, primers used in the first round of PCR were VJ23
(5'-ATGGGCGCGAGAAACTCCGTC-3') and SIVGAGrev
(5'- CCCCTGTATCCAATAATACT -3'). 2 nested PCR were
used in a second round of PCR with VJ23 and SIVG3 (5'
TGTTGTCTGTACATCCACTGGAT 3'), SIVG1 (5' AGCG-
GCAGAGGAGGAAATTAC 3') and VJ25 (5'-CTACT-
GGTCTCCTCCAAAG 3') respectively (encompassing the
entire gag gene). Each initial reaction contained 1 µg
Post-challenge CTL responses of lipopeptide-vaccinated macaques 109 and 129, evaluated at weeks 10 and 53 for macaque 109, weeks 13 and 47 for macaque 129Figure 3
Post-challenge CTL responses of lipopeptide-vaccinated macaques 109 and 129, evaluated at weeks 10 and 53 for 
macaque 109, weeks 13 and 47 for macaque 129. The target cells were autologous B-LCL cells alone (❍) or sensitized by short 
epitopic peptides: NEF 101–110 (), NEF 116–126 (), NEF 128–136 (▲), NEF 169–178 (X), NEF 201–211 (*), NEF 211–219 
(-), NEF 215–225 (●) and GAG 266–275 (+).
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ond round. The reactions were carried out in a DNA ther-
mocycler 9600 (Perkin Elmer, Branchburg, NJ) for 40
cycles (1 min at 96°C for the first cycle and 30 sec at 95°C,
30 sec at 55°C and 1 min at 72°C for the subsequent
ones) with a final incubation at 72°C for 5 min. Ampli-
fied products were visualized on 1.5% agarose gels after
staining with ethidium bromide.
Reverse transcription-PCR (RT-PCR)
Viral RNA was extracted from 400 µl of the viral stock
using 300 µl phenol acid (Appligene Oncor, Illkirch,
France) and 300 µl extraction buffer (7 M urea, 0.35 M
NaCl, 10 mM Tris-HCl pH 7.5, 10 mM EDTA, 1% SDS).
After vortexing and centrifugation, the supernatant was
extracted twice with phenol, twice with chloroform, and
then ethanol-precipitated with 2 µg of tRNA. Following
centrifugation, the RNA pellet was washed with 70% eth-
anol, dried, and resuspended in 50 µl sterile water. Five µl
were reverse-transcribed for one hour at 37°C in 25 µl
reaction mixture containing 50 mM Tris-HCl pH 8.3, 75
mM KCl, 3 mM MgCl2, 8 mM DTT, 400 µM each dNTP,
50 pmol primers nef2 and nef1, 30 U RNAsin (Promega,
Madison, WI), and 200 U Mo-MuLV reverse transcriptase
(Gibco BRL). The PCR mix was incubated for 5 min at
90°C, and 5 µl of the cDNA mixture was amplified under
the same PCR conditions as above, using VJ11 and VJ12 as
primers.
Cloning and sequencing
To estimate viral population diversity and eliminate clon-
ing bias, multiple plasmid subclones derived from the
same viral template by using endpoint DNA dilution tech-
niques were sequences. The proviral DNA copy number
used in each PCR was approximated by duplicate 10-fold
serial dilutions of DNA followed by nested PCR capable of
amplifying a single provirus (as described above). The
highest dilution yielding a positive PCR was used to esti-
mate the proviral copy number. This end-point dilution
of all PBMC DNA generated PCR products that were
directly sequenced after purification on a Qiaquik column
(Qiagen Courtaboeuf, Les Ullis, France). Following purifi-
cation, 50 ng of the PCR product was ligated overnight at
15°C with 50 ng of pTAG vector (R&D Systems Europe,
Abingdon, UK) in 10 µl of buffer containing 50 mM Tris-
HCl pH 7.6, 10 mM MgCl2, 1 mM ATP, 1 mM DTT, 5%
PEG-8000, and 1 U of T4 DNA ligase (Gibco). A volume
of 0.1 µl of the ligation product was transferred into E. coli
TG1, and the few white colonies obtained on Luria Broth
(Amersham Pharmacia Biotech, Amersham, UK) plates
with ampicillin were selected. DNA was extracted using
the Easy Prep Plasmid Prep kit (Pharmacia) and 500 ng
were sequenced using the Dye Terminator chemistry on a
373A sequencer (ABI, Perkin Elmer). All sequences were
aligned using the SeqEd program.
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